{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:22:00Z","timestamp":1787664120656,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Hebei Natural Science Foundation","doi-asserted-by":"crossref","award":["H2023206259"],"award-info":[{"award-number":["H2023206259"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Science Research Project of Hebei","award":["20220162"],"award-info":[{"award-number":["20220162"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04484-y","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:54:26Z","timestamp":1783166066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Cuiying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"4484_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC et al (2020) Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer 20:323\u2013342. https:\/\/doi.org\/10.1038\/s41568-020-0247-0","journal-title":"Nat Rev Cancer"},{"key":"4484_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30103-4","volume":"7","author":"L Wang","year":"2020","unstructured":"Wang L, Wang JW (2020) Extranodal natural-killer T-cell lymphoma: experience from China. Lancet Haematol 7:e441. https:\/\/doi.org\/10.1016\/S2352-3026(20)30103-4","journal-title":"Lancet Haematol"},{"key":"4484_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01904-w","volume":"23","author":"Y Luan","year":"2024","unstructured":"Luan Y, Li X, Luan Y, Luo J, Dong Q et al (2024) Therapeutic challenges in peripheral T-cell lymphoma. Mol Cancer 23:2. https:\/\/doi.org\/10.1186\/s12943-023-01904-w","journal-title":"Mol Cancer"},{"key":"4484_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41375-020-01042-y","volume":"35","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang Y, Liu X, He X, Zhang LL et al (2021) Progression-free survival at 24 months and subsequent survival of patients with extranodal NK\/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia 35:1671\u20131682. https:\/\/doi.org\/10.1038\/s41375-020-01042-y","journal-title":"Leukemia"},{"key":"4484_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"4484_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ et al (2016) PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol 9:109. https:\/\/doi.org\/10.1186\/s13045-016-0341-7","journal-title":"J Hematol Oncol"},{"key":"4484_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","volume":"96","author":"JC Jo","year":"2017","unstructured":"Jo JC, Kim M, Choi Y, Kim HJ, Kim JE et al (2017) Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol 96:25\u201331. https:\/\/doi.org\/10.1007\/s00277-016-2818-4","journal-title":"Ann Hematol"},{"key":"4484_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000500974","volume":"143","author":"H Muhamad","year":"2020","unstructured":"Muhamad H, Suksawai N, Assanasen T, Polprasert C, Bunworasate U et al (2020) Programmed cell death 1 and programmed cell death ligands in extranodal natural killer\/T cell lymphoma: expression pattern and potential prognostic relevance. Acta Haematol 143:78\u201388. https:\/\/doi.org\/10.1159\/000500974","journal-title":"Acta Haematol"},{"key":"4484_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12885-025-13812-x","volume":"25","author":"J Yang","year":"2025","unstructured":"Yang J, Xue X, Ma Y, Wang X, Xu C (2025) Efficacy and safety of PD-1\/PD-L1 inhibitors for natural killer\/T-cell lymphoma: a single-arm meta-analysis. BMC Cancer 25:385. https:\/\/doi.org\/10.1186\/s12885-025-13812-x","journal-title":"BMC Cancer"},{"key":"4484_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","volume":"6","author":"R Tao","year":"2021","unstructured":"Tao R, Fan L, Song Y, Hu Y, Zhang W et al (2021) Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4). Signal Transduct Target Ther 6:365. https:\/\/doi.org\/10.1038\/s41392-021-00768-0","journal-title":"Signal Transduct Target Ther"},{"key":"4484_CR11","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang H, Tao R, Hao S, Yang Y, Cen H et al (2023) Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J Clin Oncol 41:3032\u20133041. https:\/\/doi.org\/10.1200\/JCO.22.02367","journal-title":"J Clin Oncol"},{"key":"4484_CR12","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","volume":"7","author":"E Bachy","year":"2023","unstructured":"Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G et al (2023) Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study. Blood Adv 7:4435\u20134447. https:\/\/doi.org\/10.1182\/bloodadvances.2022009575","journal-title":"Blood Adv"},{"key":"4484_CR13","doi-asserted-by":"publisher","first-page":"e823","DOI":"10.1016\/S2352-3026(25)00228-5","volume":"12","author":"E Tse","year":"2025","unstructured":"Tse E, Querfeld C, Ishitsuka K, Kwong YL (2025) Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas. Lancet Haematol 12:e823\u2013e835. https:\/\/doi.org\/10.1016\/S2352-3026(25)00228-5","journal-title":"Lancet Haematol"},{"key":"4484_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000004017","author":"S Wang","year":"2026","unstructured":"Wang S, Qiu Y, Zhao W (2026) Targeting signaling pathways in lymphoma: from molecular mechanisms to clinical breakthroughs. Chin Med J (Engl). https:\/\/doi.org\/10.1097\/CM9.0000000000004017","journal-title":"Chin Med J (Engl)"},{"key":"4484_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09825-5","volume":"22","author":"C He","year":"2022","unstructured":"He C, Wang C, Liu H, Shan B (2022) Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells. BMC Cancer 22:724. https:\/\/doi.org\/10.1186\/s12885-022-09825-5","journal-title":"BMC Cancer"},{"key":"4484_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-025-00843-2","author":"E Mishima","year":"2025","unstructured":"Mishima E, Nakamura T, Doll S, Proneth B, Fedorova M et al (2025) Recommendations for robust and reproducible research on ferroptosis. Nat Rev Mol Cell Biol. https:\/\/doi.org\/10.1038\/s41580-025-00843-2","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4484_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1012505","volume":"9","author":"Y Liang","year":"2022","unstructured":"Liang Y, Su S, Lun Z, Zhong Z, Yu W et al (2022) Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma. Front Mol Biosci 9:1012505. https:\/\/doi.org\/10.3389\/fmolb.2022.1012505","journal-title":"Front Mol Biosci"},{"key":"4484_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S et al (2023) Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1\/L1 response. Adv Sci (Weinh) 10:e2203973. https:\/\/doi.org\/10.1002\/advs.202203973","journal-title":"Adv Sci (Weinh)"},{"key":"4484_CR19","doi-asserted-by":"publisher","first-page":"31099","DOI":"10.1021\/acsomega.5c04710","volume":"10","author":"L Liang","year":"2025","unstructured":"Liang L, Chen Z, Lei D, Mo C, Lan D et al (2025) APG-115 induces SLC7A11-mediated ferroptosis and upregulates PD-L1 expression in thyroid cancer. ACS Omega 10:31099\u201331107. https:\/\/doi.org\/10.1021\/acsomega.5c04710","journal-title":"ACS Omega"},{"key":"4484_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114868","volume":"43","author":"K Xiao","year":"2024","unstructured":"Xiao K, Zhang S, Peng Q, Du Y, Yao X et al (2024) PD-L1 protects tumor-associated dendritic cells from ferroptosis during immunogenic chemotherapy. Cell Rep 43:114868. https:\/\/doi.org\/10.1016\/j.celrep.2024.114868","journal-title":"Cell Rep"},{"key":"4484_CR21","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.7150\/ijbs.93592","volume":"20","author":"B Yang","year":"2024","unstructured":"Yang B, Shu W, Hu J, Wang Z, Wu J et al (2024) Aberrant expression of SLC7A11 impairs the antimicrobial activities of macrophages in Staphylococcus aureus osteomyelitis in mice. Int J Biol Sci 20:2555\u20132575. https:\/\/doi.org\/10.7150\/ijbs.93592","journal-title":"Int J Biol Sci"},{"key":"4484_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.583050","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Yang Y, Qi S, Wang Y, He X et al (2020) Treatment, survival, and prognosis of advanced-stage natural killer\/T-cell lymphoma: an analysis from the China Lymphoma Collaborative Group. Front Oncol 10:583050. https:\/\/doi.org\/10.3389\/fonc.2020.583050","journal-title":"Front Oncol"},{"key":"4484_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01483-9","volume":"16","author":"XP Tian","year":"2023","unstructured":"Tian XP, Cao Y, Cai J, Zhang YC, Zou QH et al (2023) Novel target and treatment agents for natural killer\/T-cell lymphoma. J Hematol Oncol 16:78. https:\/\/doi.org\/10.1186\/s13045-023-01483-9","journal-title":"J Hematol Oncol"},{"key":"4484_CR24","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1097\/CM9.0000000000003152","volume":"137","author":"C Wang","year":"2024","unstructured":"Wang C, Wang L (2024) Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer\/T cell lymphoma. Chin Med J (Engl) 137:2308\u20132324. https:\/\/doi.org\/10.1097\/CM9.0000000000003152","journal-title":"Chin Med J (Engl)"},{"key":"4484_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-024-02266-y","volume":"38","author":"Y Li","year":"2024","unstructured":"Li Y, Chen K, Chen B, Zeng R, He Y et al (2024) Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma. Leukemia 38:1553\u20131563. https:\/\/doi.org\/10.1038\/s41375-024-02266-y","journal-title":"Leukemia"},{"key":"4484_CR26","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/ol.2014.2356","volume":"8","author":"L Han","year":"2014","unstructured":"Han L, Liu F, Li R, Li Z, Chen X et al (2014) Role of programmed death ligands in effective T-cell interactions in extranodal natural killer\/T-cell lymphoma. Oncol Lett 8:1461\u20131469. https:\/\/doi.org\/10.3892\/ol.2014.2356","journal-title":"Oncol Lett"},{"key":"4484_CR27","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","volume":"66","author":"T Nagato","year":"2017","unstructured":"Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K et al (2017) Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 66:877\u2013890. https:\/\/doi.org\/10.1007\/s00262-017-1987-x","journal-title":"Cancer Immunol Immunother"},{"key":"4484_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","volume":"469","author":"WY Kim","year":"2016","unstructured":"Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS et al (2016) Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis. Virchows Arch 469:581\u2013590. https:\/\/doi.org\/10.1007\/s00428-016-2011-0","journal-title":"Virchows Arch"},{"key":"4484_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00277-019-03643-9","volume":"98","author":"L Zeng","year":"2019","unstructured":"Zeng L, Huang W, Cao Z, Zheng B, Liu X et al (2019) The correlation of clinicopathological features and prognosis in extranodal natural killer\/T cell lymphoma: a report of 42 cases in the early stage. Ann Hematol 98:1467\u20131476. https:\/\/doi.org\/10.1007\/s00277-019-03643-9","journal-title":"Ann Hematol"},{"key":"4484_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1907059","volume":"10","author":"HX He","year":"2021","unstructured":"He HX, Gao Y, Fu JC, Zhou QH, Wang XX et al (2021) VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma. Oncoimmunology 10:1907059. https:\/\/doi.org\/10.1080\/2162402X.2021.1907059","journal-title":"Oncoimmunology"},{"key":"4484_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126447","author":"M Zanelli","year":"2024","unstructured":"Zanelli M, Fragliasso V, Parente P, Bisagni A, Sanguedolce F et al (2024) Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25126447","journal-title":"Int J Mol Sci"},{"key":"4484_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","volume":"33","author":"J Cho","year":"2020","unstructured":"Cho J, Kim SJ, Park WY, Kim J, Woo J et al (2020) Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Mod Pathol 33:603\u2013615. https:\/\/doi.org\/10.1038\/s41379-019-0392-8","journal-title":"Mod Pathol"},{"key":"4484_CR33","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2020007247","volume":"136","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Lim JQ, Laurensia Y, Cho J, Yoon SE et al (2020) Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study. Blood 136:2754\u20132763. https:\/\/doi.org\/10.1182\/blood.2020007247","journal-title":"Blood"},{"key":"4484_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12:599\u2013620. https:\/\/doi.org\/10.1007\/s13238-020-00789-5","journal-title":"Protein Cell"},{"key":"4484_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu X, Nie L, Zhang Y, Yan Y, Wang C et al (2023) Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol 25:404\u2013414. https:\/\/doi.org\/10.1038\/s41556-023-01091-2","journal-title":"Nat Cell Biol"},{"key":"4484_CR36","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ymthe.2021.03.013","volume":"29","author":"N Liu","year":"2021","unstructured":"Liu N, Zhang J, Yin M, Liu H, Zhang X et al (2021) Inhibition of xCT suppresses the efficacy of anti-PD-1\/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther 29:2321\u20132334. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.013","journal-title":"Mol Ther"},{"key":"4484_CR37","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.chembiol.2024.10.014","volume":"31","author":"M Wang","year":"2024","unstructured":"Wang M, Prachyathipsakul T, Silva CA, Xiong C, Goel S et al (2024) Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates. Cell Chem Biol 31:2039-2051 e6. https:\/\/doi.org\/10.1016\/j.chembiol.2024.10.014","journal-title":"Cell Chem Biol"},{"key":"4484_CR38","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/hep.32062","volume":"74","author":"Q He","year":"2021","unstructured":"He Q, Liu M, Huang W, Chen X, Zhang B et al (2021) IL-1beta-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and colony-stimulating factor 1. Hepatology 74:3174\u20133193. https:\/\/doi.org\/10.1002\/hep.32062","journal-title":"Hepatology"},{"key":"4484_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101415","volume":"5","author":"S Wang","year":"2024","unstructured":"Wang S, Zhu L, Li T, Lin X, Zheng Y et al (2024) Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. Cell Rep Med 5:101415. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101415","journal-title":"Cell Rep Med"},{"key":"4484_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gijon M, Kennedy PD et al (2019) CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569:270\u2013274. https:\/\/doi.org\/10.1038\/s41586-019-1170-y","journal-title":"Nature"},{"key":"4484_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013269","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yu R, Li Q, Song S, Fu Y et al (2025) Epigenetic suppression of Nrf2-Slc40a1 axis induces ferroptosis and enhances immunotherapy in pancreatic cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2025-013269","journal-title":"J Immunother Cancer"},{"key":"4484_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102685","volume":"65","author":"Z Wang","year":"2026","unstructured":"Wang Z, Liu H, Liang J, Zhang Y, Cho WC et al (2026) Ferroptosis induction enhances anti-PD-1 efficacy in NSCLC via HIF-1alpha\/PD-L1 modulation. Transl Oncol 65:102685. https:\/\/doi.org\/10.1016\/j.tranon.2026.102685","journal-title":"Transl Oncol"},{"key":"4484_CR43","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.scib.2023.09.029","volume":"68","author":"J Xiong","year":"2023","unstructured":"Xiong J, Dai YT, Wang WF, Zhang H, Wang CF et al (2023) GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis. Sci Bull (Beijing) 68:2607\u20132619. https:\/\/doi.org\/10.1016\/j.scib.2023.09.029","journal-title":"Sci Bull (Beijing)"},{"key":"4484_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303913","volume":"10","author":"YQ Li","year":"2023","unstructured":"Li YQ, Luo CL, Jiang JX, He S, Liu Y et al (2023) Single-cell analysis reveals malignant cells reshape the cellular landscape and foster an immunosuppressive microenvironment of extranodal NK\/T-cell lymphoma. Adv Sci (Weinh) 10:e2303913. https:\/\/doi.org\/10.1002\/advs.202303913","journal-title":"Adv Sci (Weinh)"},{"key":"4484_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2212532","volume":"12","author":"X Feng","year":"2023","unstructured":"Feng X, Meng M, Li H, Gao Y, Song W et al (2023) T-cell dysfunction in natural killer\/T-cell lymphoma. Oncoimmunology 12:2212532. https:\/\/doi.org\/10.1080\/2162402X.2023.2212532","journal-title":"Oncoimmunology"},{"key":"4484_CR46","doi-asserted-by":"publisher","first-page":"113626","DOI":"10.1016\/j.isci.2025.113626","volume":"28","author":"S Ma","year":"2025","unstructured":"Ma S, Huang B, Wang J, Lv R, Dai DL et al (2025) Single-cell and spatial transcriptomics reveal intratumor heterogeneity and immune evasion in natural killer\/T cell lymphoma. iScience 28:113626. https:\/\/doi.org\/10.1016\/j.isci.2025.113626","journal-title":"iScience"},{"key":"4484_CR47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.it.2025.03.007","volume":"46","author":"L Yuan","year":"2025","unstructured":"Yuan L, Zhong L, Krummenacher C, Zhao Q, Zhang X (2025) Epstein-Barr virus-mediated immune evasion in tumor promotion. Trends Immunol 46:386\u2013402. https:\/\/doi.org\/10.1016\/j.it.2025.03.007","journal-title":"Trends Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04484-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04484-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04484-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:52:26Z","timestamp":1787662346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04484-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4484"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04484-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human tissue samples in this study were collected and used with the approval of the Institutional Review Board (IRB) of the Fourth Hospital of Hebei Medical University (2023KS273).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}